NCT00975182View on ClinicalTrials.gov

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

Interventions

DRUG

GDC-0941

Oral repeating dose

DRUG

erlotinib HCl

Oral repeating dose

Trial Locations (4)

80045

Aurora

08903

New Brunswick

1066 EC

Amsterdam

3508 GA

Utrecht

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY